HOME >> BIOLOGY >> NEWS
'Second messenger' NAADP shows fast, dose-related impact on satiety cycle

San Diego (April 3, 2005) One traditional approach to pharmaceutical design uses so-called "first messengers" hormones, other natural facilitators or synthetic products to initiate various cellular cascades for the desired physiological effect. To date, despite concerted efforts at all levels of research, this approach has failed to develop a truly successful obesity drug to address this major global health problem.

Enter a recently discovered and already controversial natural molecule called nicotinic acid adenine dinucleotide phosphate (NAADP), which is active in cells from plants to humans. NAADP is thought to be a so-called "second messenger," because it works from inside cells, rather than externally. However its mode operation remains unknown and controversial in several aspects.

Results of a new study "establishes NAADP as a new second messenger, and the study of this novel molecule has potential to extend its clinical significance, possibly as a candidate for treating obesity," according to the lead author, Michiko Yamasaki at the Department of Pharmacology, University of Oxford, United Kingdom.

Yamasaki is presenting the research at the 35th Congress of the International Union of Physiological Sciences in San Diego, March 31 - April 5, 2005.

*Paper presentation and "controversy" appearance: "Rapid, selective and dose-dependent elevation of the second messenger NAADP," 12:30 p.m.-3 p.m. Tuesday April 5, Physiology 932.3/board #A438. On view 7:30 a.m. - 4 p.m.

In addition, Ms. Yamasaki was chosen to participate in a special "controversy" session #654 of the Calcium Signaling Track on April 4 in room 29C of the Convention Center beginning at 10:30; her presentation is scheduled for 11:45 a.m.

The team working on the study was comprised of Michiko Yamasaki, Grant Churchill and Antony Galione at the Department of Pharmacology, University of Oxford; Sandip Patel at University College London; and Jose M. Cancel
'"/>


3-Apr-2005


Page: 1 2 3

Related biology news :

1. Clones on task serve greater good, evolutionary study shows
2. Research shows skeleton to be endocrine organ
3. An early ape shows its hand
4. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
5. Huntingtons disease study shows animal models on target
6. Research shows NPD1 protects a key component of vision
7. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
8. Chitin from lobster shell shows great healing and bio-stimulant properties
9. Study shows cane sugar, corn sweeteners have similar effects on appetite
10. New research shows vaginal bacteria vary among healthy women, need customized treatment
11. Global warming is evaporating Arctic ponds, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... CA (PRWEB) , ... October 11, 2017 , ... ... upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the ... system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
Breaking Biology Technology:
Cached News: